FDA guidance on demonstrating effectiveness for drugs and biologics
FDA provides guidance on evidence of effectiveness.
Related Articles
DENGVAXIA
DENGVAXIA For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 9…
Second Annual FDA ASCO WORKSHOP
Optimizing Dosage Selection Strategies in Combination Cancer Therapies.
Keep newborns and infants out of direct sunlight
When you go outdoors with your infant, it’s important to keep your little one out of the sun. Sunscreen isn’t the answer.
Heinen’s Issues Allergy Alert on Undeclared Peanuts and Almonds in Heinen’s Fresh Ground Cashew Butter
Heinen’s of Warrensville Heights, OH is voluntarily recalling Heinen’s Fresh Ground Cashew Butter, due to the possibility that it may contain undeclared Peanuts or Almonds.…
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
The FDA approved the first drug for the prevention of RSV lower respiratory tract disease in babies and toddlers.
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
The FDA approved the first drug for the prevention of RSV lower respiratory tract disease in babies and toddlers.
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and…
Outsmarting Poison Ivy and Other Poisonous Plants
Poison ivy, poison oak, and poison sumac are a hazard year-round. Here are tips for preventing and treating the itchy rash and blisters.
Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs
FDA’s 5 guidance documents provide details for drug development for neurological conditions such as ALS and Alzheimer’s disease
